Literature DB >> 32436298

Fluoropyrimidine-Associated Cardiotoxicity: Probably Not So Rare As It Seems.

Chiara Lestuzzi1, Lucia Tartuferi1, Elda Viel1, Angela Buonadonna2, Emanuela Vaccher2, Massimiliano Berretta2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32436298      PMCID： PMC7418346          DOI： 10.1634/theoncologist.2020-0053

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  8 in total

1.  Clinical and electrocardiography changes in patients treated with capecitabine.

Authors:  Dogan Koca; Tarik Salman; Ilkay Tugba Unek; Ilhan Oztop; Hulya Ellidokuz; Murat Eren; Ugur Yilmaz
Journal:  Chemotherapy       Date:  2011-10-12       Impact factor: 2.544

2.  Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle.

Authors:  Søren Astrup Jensen; Philip Hasbak; Jann Mortensen; Jens Benn Sørensen
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

3.  Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.

Authors:  Søren Astrup Jensen; Jens Benn Sørensen
Journal:  Cancer Chemother Pharmacol       Date:  2006-01-18       Impact factor: 3.333

4.  Fluoropyrimidine-Associated Cardiotoxicity: A Retrospective Case-Control Study.

Authors:  Inbar Raber; Sarah Warack; Jaya Kanduri; Abby Pribish; Anuradha Godishala; Arielle Abovich; Anna Orbite; Sujithraj Dommaraju; Morgan Frazer; Mary Linton Peters; Aarti Asnani
Journal:  Oncologist       Date:  2019-12-16

5.  Effort myocardial ischemia during chemotherapy with 5-fluorouracil: an underestimated risk.

Authors:  C Lestuzzi; E Vaccher; R Talamini; A Lleshi; N Meneguzzo; E Viel; S Scalone; L Tartuferi; A Buonadonna; L Ejiofor; H-J Schmoll
Journal:  Ann Oncol       Date:  2014-02-20       Impact factor: 32.976

Review 6.  5-fluorouracil and cardiotoxicity: a review.

Authors:  Jaskanwal D Sara; Jasvinder Kaur; Ryan Khodadadi; Muneeb Rehman; Ronstan Lobo; Sakti Chakrabarti; Joerg Herrmann; Amir Lerman; Axel Grothey
Journal:  Ther Adv Med Oncol       Date:  2018-06-18       Impact factor: 8.168

7.  Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study.

Authors:  Christos Kosmas; Manolis S Kallistratos; Petros Kopterides; John Syrios; Helias Skopelitis; Nicolaos Mylonakis; Athanasios Karabelis; Nicolas Tsavaris
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.322

8.  Cardiotoxicity of 5-fluorouracil and capecitabine in Chinese patients: a prospective study.

Authors:  Jianjun Peng; Chao Dong; Chang Wang; Weihua Li; Hao Yu; Min Zhang; Qun Zhao; Bo Zhu; Jun Zhang; Wenliang Li; Fenghua Wang; Qiong Wu; Wenhao Zhou; Ying Yuan; Meng Qiu; Gong Chen
Journal:  Cancer Commun (Lond)       Date:  2018-05-11
  8 in total
  4 in total

1.  In Reply.

Authors:  Inbar Raber; Mary Linton Peters; Aarti Asnani
Journal:  Oncologist       Date:  2020-06-17

2.  Treatment-Related Coronary Disorders of Fluoropyrimidine Administration: A Systematic Review and Meta-Analysis.

Authors:  Yajie Lu; Shizhou Deng; Qiongyi Dou; Wei Pan; Qingqing Liu; Hongchen Ji; Xiaowen Wang; Hong-Mei Zhang
Journal:  Front Pharmacol       Date:  2022-05-13       Impact factor: 5.988

Review 3.  Fluoropyrimidine-induced cardiotoxicity.

Authors:  Andrada Larisa Deac; Claudia Cristina Burz; Ioana Corina Bocsan; Anca Dana Buzoianu
Journal:  World J Clin Oncol       Date:  2020-12-24

Review 4.  Cardiac Computed Tomography in Cardio-Oncology: JACC: CardioOncology Primer.

Authors:  Juan C Lopez-Mattei; Eric H Yang; Maros Ferencik; Lauren A Baldassarre; Susan Dent; Matthew J Budoff
Journal:  JACC CardioOncol       Date:  2021-12-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.